Neal Walker - 01 Feb 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
President and CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
03 Feb 2022, 15:43:23 UTC
Previous filing
10 Jun 2021
Next filing
11 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +10,800 +0.88% 1,242,982 01 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -10,800 -100% $0.000000* 0 01 Feb 2022 Common Stock 10,800 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The shares underlying these restricted stock units vested on February 1, 2022.